Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) traded up 1.6% on Tuesday . The stock traded as high as $8.85 and last traded at $8.79, with a volume of 106,025 shares. The stock had previously closed at $8.65.

Several equities research analysts recently weighed in on the company. Canaccord Genuity set a $22.00 price objective on Aquinox Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, July 21st. Needham & Company LLC started coverage on Aquinox Pharmaceuticals in a research note on Thursday, May 12th. They issued a “buy” rating and a $25.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. Aquinox Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $19.86.

The company has a 50-day moving average of $7.25 and a 200 day moving average of $8.53. The company’s market capitalization is $150.77 million.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its quarterly earnings results on Tuesday, May 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.04. Analysts expect that Aquinox Pharmaceuticals Inc. will post ($1.79) earnings per share for the current year.

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.